Safety study of Long-term Safety and Efficacy of Solriamfetol in Binge-Eating disorders
Researchers are comparing Solriamfetol and placebo, tracking side effects to assess long-term safety in adults with binge eating.
Understand this study
What is this study about?
Researchers are comparing Solriamfetol and placebo, tracking side effects to assess long-term safety in adults with binge eating.
Who could participate?
Listed age limits: 18 years to 56 years.
- Listed locations
- Encino and 32 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Enrolling By Invitation
- Enrollment listed in the registry
- 236
- Sponsor
- Axsome Therapeutics, Inc.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 56 Years
- Official registry ID
- NCT06878976
- Official title
Show the full official title
An Open-Label and Double-Blind, Randomized Withdrawal Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Adults With Binge Eating Disorder
Recruitment & locations
Encino · Long Beach · Santa Ana
29 more locations
- Walnut Creek
- West Covina
- Colorado Springs
- Cromwell
- Fort Myers
- Jacksonville
- Lauderhill
- Miami
- Miami Lakes
- Orlando
- Marietta
- Overland Park
- Boston
- Saint Charles
- Cherry Hill
- Mount Kisco
- New York
- Raleigh
- Cincinnati
- Mason
- Middleburg Heights
- North Canton
- Portland
- Allentown
- North Charleston
- Memphis
- Austin
- Dallas
- San Antonio
Interested in joining this study?
Questions about this study
What is this study about?
Researchers are comparing Solriamfetol and placebo, tracking side effects to assess long-term safety in adults with binge eating.
Who is behind this study?
The study sponsor is Axsome Therapeutics, Inc.
Does this study involve medication?
Yes. The study involves medication, including Solriamfetol and Placebo.
Who can participate?
Listed age limits: 18 years to 56 years.
Is this study still recruiting?
The registry lists this study as enrolling by invitation.
